Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A
S. Kepa
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorB. Horvath
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorS. Reitter-Pfoertner
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorM. Schemper
Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorP. Quehenberger
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorM. Grundbichler
Division of Haematology and Oncology, Department of Internal Medicine III, Medical University of Salzburg, Salzburg, Austria
Search for more papers by this authorM. Heistinger
Department of Internal Medicine I, Clinical Centre of Klagenfurt am Woerthersee, Klagenfurt am Woerthersee, Austria
Search for more papers by this authorP. Neumeister
Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorC. Mannhalter
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorCorresponding Author
I. Pabinger
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Correspondence: Ingrid Pabinger, Medical University of Vienna, Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Tel.: +43 1 40400 44480; fax: +43 1 4040027430;
e-mail: [email protected]
Search for more papers by this authorS. Kepa
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorB. Horvath
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorS. Reitter-Pfoertner
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorM. Schemper
Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorP. Quehenberger
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorM. Grundbichler
Division of Haematology and Oncology, Department of Internal Medicine III, Medical University of Salzburg, Salzburg, Austria
Search for more papers by this authorM. Heistinger
Department of Internal Medicine I, Clinical Centre of Klagenfurt am Woerthersee, Klagenfurt am Woerthersee, Austria
Search for more papers by this authorP. Neumeister
Division of Haematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Search for more papers by this authorC. Mannhalter
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorCorresponding Author
I. Pabinger
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Correspondence: Ingrid Pabinger, Medical University of Vienna, Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Tel.: +43 1 40400 44480; fax: +43 1 4040027430;
e-mail: [email protected]
Search for more papers by this authorSummary
In haemophilia A patients factor VIII (FVIII) recovery and half-life can vary substantially. There are parameters known to modulate FVIII pharmacokinetics (PK), but they explain only about 34% of the variability. The aim of this study was to identify new parameters that influence FVIII PK and thus to expand the current knowledge. FVIII PK were determined in 42 haemophilia A patients (37 severe, 5 moderate) without inhibitor. Patients' characteristics and laboratory parameters were evaluated for an association with FVIII PK. We analysed plasma levels of low-density lipoprotein receptor-related protein 1 (LRP1) and protein C (PC) activity, which had been hypothesized to influence FVIII activity. Furthermore, four variations in intron 6 of the LRP1 gene, which had been shown to influence LRP1, were investigated. FVIII half-life differed widely from 6.2 to 20.7 h, with a median of 10.0 h. Patients with blood group O had shorter FVIII half-life compared to patients with non-O blood group (median FVIII half-life 9.0 h vs. 10.4 h, P = 0.018). Age was significantly associated with FVIII half-life (r = 0.32, P = 0.035). Besides age, also VWF antigen (r = 0.52, P < 0.001) and blood group (r = −0.37, P = 0.015) was associated with FVIII half-life. No correlation was found with FVIII- or LRP1-genotype, LRP1 or PC concentrations. Our data showed large differences in FVIII PK between individual patients and revealed age, blood group and VWF levels as important determining factors for FVIII half-life. FVIII genotype or levels of LRP1 or PC had no influence on FVIII PK.
References
- 1Collins PW, Björkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269–75.
- 2Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689–97.
- 3Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
- 4Fischer K, Astermark J, van der Bom JG et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753–60.
- 5Björkman S, Blanchette VS, Fischer K et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010; 8: 730–6.
- 6Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319–26.
- 7van Dijk K, van der Bom JG, Lenting PJ et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90: 494–8.
- 8Henrard S, Speybroeck N, Hermans C. Body weight and fat mass index as strong predictors of factor VIII in vivo recovery in adults with hemophilia A. J Thromb Haemost 2011; 9: 1784–90.
- 9Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica 2013; 98: 1481–6.
- 10Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989–98.
- 11Fischer K, Pendu R, van Schooten CJ et al. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009; 4: e6745.
- 12Bovenschen N, van Dijk KW, Havekes LM, Mertens K, van Vlijmen BJM. Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice. Br J Haematol 2004; 126: 722–5.
- 13Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999; 274: 37685–92.
- 14Quinn KA, Pye VJ, Dai YP, Chesterman CN, Owensby DA. Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP). Exp Cell Res 1999; 251: 433–41.
- 15Bovenschen N, Mertens K, Hu L, Havekes LM, van Vlijmen BJM. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood 2005; 106: 906–12.
- 16Bovenschen N, Herz J, Grimbergen JM et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood 2003; 101: 3933–9.
- 17Bovenschen N, van Stempvoort G, Voorberg J, Mertens K, Meijer AB. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain. J Thromb Haemost 2006; 4: 1487–93.
- 18Marchetti G, Lunghi B, Legnani C et al. Contribution of low density lipoprotein receptor-related protein genotypes to coagulation factor VIII levels in thrombotic women. Haematologica 2006; 91: 1261–3.
- 19Morange PE, Tregouet DA, Frere C et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol 2005; 128: 91–9.
- 20Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486–9.
- 21Gennari LC, Blanco AN, Domínguez MP, Grosso SH, Lazzari MA. Endogenous or exogenous coagulation factor level and the response to activated protein C. Thromb Res 2006; 118: 269–73.
- 22Lee M, Morfini M, Negrier C, Chamouard V. The pharmacokinetics of coagulation factors. Haemophilia 2006; 12(Suppl 3): 1–7.
- 23Lee M, Morfini M, Schulman S, Ingerslev J and the FVIII/FIX Scientific and Standardization Committee. Scientific and Standardization Committee Communication: the Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Available at http://c.ymcdn.com/sites/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf. Accessed April 02, 2014.
- 24Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007; 13: 2–8.
- 25Björkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia 2011; 17: e239–40.
- 26Björkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612–8.
- 27Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247–51.
- 28Fijnvandraat K, Peters M, ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474–6.
- 29Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995; 85: 3150–7.
- 30Nogami K, Shima M, Nishiya K et al. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation. Blood 2002; 99: 3993–8.
- 31Deitcher SR, Tuller J, Johnson JA. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia 1999; 5: 88–95.
- 32Tang L, Leong L, Sim D et al. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo. Haemophilia 2013; 19: 539–45.
- 33Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014; 20(Suppl 4): 99–105.
- 34Shapiro AD. Long-lasting recombinant factor VIII proteins for hemophilia A. Hematology Am SocHematolEduc Program. 2013; 2013: 37–43.
- 35Takeyama M, Wintermute JM, Manithody C, Rezaie AR, Fay PJ. Variable contributions of basic residues forming an APC exosite in the binding and inactivation of factor VIIIa. Biochemistry 2013; 52: 2228–35.
- 36Cramer TJ, Gale AJ. Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation. Br J Haematol 2011; 153: 644–54.